- Poster presentation
- Open Access
Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
© Ariën et al; licensee BioMed Central Ltd. 2011
- Published: 3 October 2011
- Bacterial Vaginosis
- Female Genital Tract
- Bench Mark
- Vaginal Flora
- Dual Chamber
In search of antiretrovirals with microbicide potential, we have synthesized a library of non-nucleoside reverse transcriptase inhibitors (NNRTIs), encompassing 71 triazine analogues. We present data on the anti-HIV activity and toxicity using a broad armamentarium of in vitro assays and models.
In a primary screen, the anti-HIV activity against the laboratory strain Ba-L and against a primary subtype C isolate was determined in the TZM-bl cell line. Cellular toxicity on TZM-bl cells was evaluated using WST-1. Subsequently, a selection of 17 compounds was further evaluated for anti-HIV activity in different primary cells, including peripheral blood mononuclear cells, dendritic cells and CD4+ T lymphocytes. In addition, the activity against NNRTI-resistantviruses (V106A, Y181C, L100I/ K103N) was tested. The toxicity profile was further investigated using blood cells and epithelial cells originating from the female genital tract (FGT) and in a dual chamber assay modeling the FGT and underlying mucosae. Finally, toxicity towards vaginal flora (reference strains of L. vaginalis, L. iners, L. jensenii, L. gasseri, L. crispatus, A vaginae, G. vaginalis) was measured for the lead molecules UAMC00838 and UAMC01009. Dapivirine (TMC120) was used as a bench mark throughout the study.
In TZM-bl cells, most of the compounds were highly active against Ba-L and subtype C, with low nanomolar EC50 values slightly above or below the EC50 of dapivirine (2.0 nM). Similar nM activities were found in primary cells for a selection of 17 compounds. Interestingly, these compounds retained fairly good potency (EC50 values = 1-300 nm) against a resistant strain carrying the NNRTI-resistance mutations V106A or Y181C. However, potency was diminished (submicromolar and micromolar EC50 values) when tested against a mutant virus carrying L100I/K103N. Compounds UAMC00838 and UAMC01009 were identified as lead molecules based on their activity/toxicity profile and chemical structure.
These novel compounds showed similar or better toxicity profiles as the bench mark molecule dapivirine, in TZM-bl cells as well as in FGT epithelial cells and in a dual chamber system modeling the FGT. Finally, while no toxicity against vaginal lactobacilli was observed up to concentrations approx. 80,000 times above the EC50 of compound UAMC00838, the growth of G. vaginalis and A vaginae was inhibited at the highest compound concentration. Compound UAMC01009 showed additional low level toxicity against L. iners and high level toxicity against L. crispatus.
We present data of highly active NNRTIs with a favorable toxicity profiles compared to the bench mark NNRTI dapivirine. Compound UAMC00838 does not affect the normal vaginal flora, but could inhibit G. vaginalis and A vaginae, which are associated with bacterial vaginosis, a risk factor for HIV acquisition. Ongoing studies on solubility and formulation will reveal their potential as intravaginal/-rectal microbicides.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.